224 related articles for article (PubMed ID: 16966722)
1. Evolution and future of biopharmaceuticals.
Health Aff (Millwood); 2006; 25(5):1270. PubMed ID: 16966722
[No Abstract] [Full Text] [Related]
2. Growing pains for biopharmaceuticals.
Ashton G
Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
[No Abstract] [Full Text] [Related]
3. Biopharmaceuticals: recent approvals and likely directions.
Walsh G
Trends Biotechnol; 2005 Nov; 23(11):553-8. PubMed ID: 16051388
[TBL] [Abstract][Full Text] [Related]
4. Biopharmaceuticals and the future of the pharmaceutical industry.
Lowe JA; Jones P
Curr Opin Drug Discov Devel; 2007 Sep; 10(5):513-4. PubMed ID: 17786848
[No Abstract] [Full Text] [Related]
5. Manufacturing, regulatory and commercial challenges of biopharmaceuticals production: a Finnish perspective.
Närhi M; Nordström K
Eur J Pharm Biopharm; 2005 Apr; 59(3):397-405. PubMed ID: 15760720
[TBL] [Abstract][Full Text] [Related]
6. Chinese biotech hamstrung by production issues.
Jia H
Nat Biotechnol; 2007 Feb; 25(2):147-8. PubMed ID: 17287733
[No Abstract] [Full Text] [Related]
7. GlaxoSmithKline pushes its labs towards 'biotech' future.
Adam D
Nature; 2001 Mar; 410(6824):5. PubMed ID: 11242002
[No Abstract] [Full Text] [Related]
8. A rollercoaster ride.
Jacobs T
Nat Biotechnol; 2006 Mar; 24(3):284. PubMed ID: 16525390
[No Abstract] [Full Text] [Related]
9. Market access for biopharmaceuticals: new challenges.
Simon F
Health Aff (Millwood); 2006; 25(5):1363-70. PubMed ID: 16966734
[TBL] [Abstract][Full Text] [Related]
10. Building biomanufacturing capacity--the chapter and verse.
Kamarck ME
Nat Biotechnol; 2006 May; 24(5):503-5. PubMed ID: 16680126
[TBL] [Abstract][Full Text] [Related]
11. Innovation in biotechnology: current and future states.
Woollett GR
Clin Pharmacol Ther; 2012 Jan; 91(1):17-20. PubMed ID: 22179626
[TBL] [Abstract][Full Text] [Related]
12. Editorial: Biotechnology in Korea--the next generation growth engine.
Lee SY
Biotechnol J; 2008 May; 3(5):562-3. PubMed ID: 18481356
[No Abstract] [Full Text] [Related]
13. Drug discovery: past, present and future.
Malik NN
Drug Discov Today; 2008 Nov; 13(21-22):909-12. PubMed ID: 18852066
[No Abstract] [Full Text] [Related]
14. The two-curve problem: high-risk challenges face those who plan a hospital's future.
Morrison JI
Health Manage Q; 1994; 16(1):11-5. PubMed ID: 10133736
[No Abstract] [Full Text] [Related]
15. Russia through the prism of the world biopharmaceutical market.
Bairamashvili DI; Rabinovich ML
Biotechnol J; 2007 Jul; 2(7):801-17. PubMed ID: 17615600
[TBL] [Abstract][Full Text] [Related]
16. [Strathmann AG: first OTC, now biotechnology. AIDS vaccines from German biotechnology research? (interview by Dr. med. Dirk Einecke)].
Strathmann G
MMW Fortschr Med; 2001 Oct; 143(42):58-9. PubMed ID: 11697293
[No Abstract] [Full Text] [Related]
17. An industry imperiled by regulatory bottlenecks.
Naughton G
Nat Biotechnol; 2001 Aug; 19(8):709-10. PubMed ID: 11479550
[No Abstract] [Full Text] [Related]
18. Western biotechs ponder follow-on possibilities.
Waltz E
Nat Biotechnol; 2008 Sep; 26(9):962-3. PubMed ID: 18779793
[No Abstract] [Full Text] [Related]
19. Big pharmas seek biotechs that deliver.
Dove A
Nat Biotechnol; 2001 May; 19(5):398. PubMed ID: 11328985
[No Abstract] [Full Text] [Related]
20. Reality check for device-drug convergence.
Ratner M
Nat Biotechnol; 2007 Feb; 25(2):157-9. PubMed ID: 17287739
[No Abstract] [Full Text] [Related]
[Next] [New Search]
